drug

ARGX-119

1 story · latest Aug 6, 2026

Status: Investigational
Trials: 3 registered trials in coverage

Relationships

Developed by argenx

Timeline

Halozyme posts record Q2 2026, raises full-year guidance on royalty growth

Aug 6Quarterly updateHalozyme Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.